Zyla Life Sciences Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2018-11-19: Form 8-K; Period of report 2018-11-16; Description 2.02 Results of Operations and Financial Condition; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 2.02.
- 2018-11-13: Form 8-K; Period of report 2018-11-13; Description 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; Details 2.02.
- 2018-10-31: Form 8-K; Period of report 2018-10-29; Description 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 1.03 Bankruptcy or Receivership; 2.04 Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure; 8.01 Other Events; Details 1.01.
- 2018-10-25: Form 8-K; Period of report 2018-10-24; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2018-11-19 | 8-K | 2018-11-16 | 2.02 Results of Operations and Financial Condition; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 2.02 On November 19, 2018, Egalet Corporation (the “Company”) issued a press release announcing its financial results for its third quarter ended September 30, 2018. 5.02 On November 16, 2018, the Board of Directors of the Company appointed Barbara Carlin, who is currently Chief Accounting Officer of the Company, as the Company’s principal financial officer. | a18-40394_18k.htm |
| 2018-11-13 | 8-K | 2018-11-13 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On November 13, 2018, Egalet Corporation (the “Company”) will make a presentation during which it will provide information about the Company, including third quarter revenue by product, to investors. 7.01 On November 13, 2018, Robert Radie, President and Chief Executive Officer of the Company, will be using the presentation furnished as Exhibit 99.1 hereto at the Stifel 2018 Healthcare Conference. | a18-40120_18k.htm |
| 2018-10-31 | 8-K | 2018-10-29 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 1.03 Bankruptcy or Receivership; 2.04 Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 1.02 previously announced discontinuation of the marketing of ARYMO ER, the Company terminated its Drug Product Manufacturing Services Agreement by and between Halo Pharmaceutical, Inc., on the one hand, and Egalet Corporation, Egalet Limited and Egalet US Inc., on the other hand, dated as of February 28, 2017 (the “Manufacturing Agreement”). 1.03 To the extent required by Item 1.03 of Form 8-K, the information contained in Items 1.01 and 7.01 of this Current Report on Form 8-K with the respect to the filing of the Chapter 11 Cases is incorporated herein by reference. 2.04 The filing of the Bankruptcy Petitions described in Items 1.01 and 7.01 constitutes an event of default that accelerated the Company’s and its subsidiaries obligations under the following existing debt instruments (the “Existing Debt Instruments”): (i) the Indenture, dated August 31, 2016, by and among Egalet, Egalet US, Egalet Limited (“Egalet UK”) and U.S. Bank National Association, as trustee and collateral agent, and the related security documents, governing the Existing Senior Secured Notes; (ii) the Indenture, dated April 7, 2015, by and among Egalet, Egalet US, Egalet UK and The Bank of New York Mellon, as trustee, governing the 5.50% Notes; and (iii) the Indenture, dated December 27, 2017, by and among Egalet, Egalet US, Egalet UK and The Bank of New York Mellon, as trustee, governing the 6.50% Notes. 5.02 To the extent required by Item 5.02 of Form 8-K, the information contained in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. 7.01 On October 30, 2018, the Debtors filed the Bankruptcy Petitions. 8.01 On October 31, 2018, Egalet issued a press release announcing its entry into the Purchase Agreement and the transactions contemplated thereby. | a18-38168_18k.htm |
| 2018-10-25 | 8-K | 2018-10-24 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | a18-37188_18k.htm |
| 2018-10-22 | 8-K | 2018-10-21 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | a18-36897_28k.htm |
| 2018-10-18 | 8-K | 2018-10-14 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On October 14, 2018, Stan Musial, Executive Vice President and Chief Financial Officer of Egalet Corporation (the “Company”), tendered his resignation as an officer of the Company effective November 9, 2018 to pursue other opportunities. | a18-36897_18k.htm |
| 2018-10-15 | 8-K | 2018-10-14 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | a18-36733_18k.htm |
| 2018-10-05 | 8-K | 2018-10-03 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | a18-36089_28k.htm |
| 2018-09-28 | 8-K | 2018-09-28 | 2.06 Material Impairments; 8.01 Other Events | 2.06 To the extent required by Item 2.06 of Form 8-K, the information contained in Item 8.01 of this Current Report on Form 8-K is incorporated herein by reference. 8.01 On September 28, 2018, Egalet Corporation (the “Company”) notified the U.S. Food and Drug Administration that, for business reasons, the Company is discontinuing the manufacture and promotion of Arymo® ER (morphine sulfate) extended-release tablets (“ARYMO ER”) effective September 28, 2018 (the “Discontinuation”). | a18-36089_18k.htm |
| 2018-09-19 | 8-K | 2018-09-18 | 1.01 Entry into a Material Definitive Agreement; 2.04 Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement; 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 7.01 Regulation FD Disclosure; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 2.04 Triggering Events that Accelerate or Increase a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement. 3.01 On September 18, 2018, the Company received written notification from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as the Company had not regained compliance with certain continued listing requirements set forth in Nasdaq’s Listing Rules related to the aggregate market value of the Company’s common stock and the bid price of the Company’s common stock, the Nasdaq Hearings Panel determined to delist the Company’s common stock from the Nasdaq Capital Market and that there will be a suspension of trading in the Company’s common stock effective at the open of business on September 19, 2018. 7.01 The Company is currently engaged, and intends to continue to engage during the Forbearance Period, in discussions with the Supporting Holders, certain holders of the 5.50% Notes and certain holders of the 6.50% Notes, in each case, subject to non-disclosure agreements, as well as its legal and financial advisors, concerning the Company’s short- and long-term capital structure and potential strategic alternatives to address its long-terms needs, including the restructuring of the terms of the Existing Notes and certain other obligations of the Company. 8.01 As previously announced, on July 31, 2018, the Company filed a Tender Offer Statement on Schedule TO with respect to the right of each holder of 5.50% Notes to sell, and the obligation of the Company to repurchase for cash, all or a portion of each such holder’s 5.50% Notes on September 19, 2018, on the terms and subject to the conditions set forth in the Fundamental Change Company Notice, Make-Whole Fundamental Change Company Notice and Offer to Repurchase to Holders of the 5.50% Convertible Senior Notes due 2020, dated July 31, 2018, as amended August 10, 2018 (the “Tender Offer”). | a18-31092_18k.htm |
| 2018-09-11 | 8-K | 2018-09-05 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 - Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. | a18-28028_18k.htm |
| 2018-08-08 | 8-K | 2018-08-08 | 2.02 Results of Operations and Financial Condition | 2.02 On August 8, 2018, Egalet Corporation (the “Company”) issued a press release announcing its financial results for its second quarter ended June 30, 2018. | a18-17983_28k.htm |
| 2018-07-11 | 8-K | 2018-07-09 | 2.02 Results of Operations and Financial Condition; 2.04 Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement; 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 2.02 The information set forth in Item 3.01 below under the heading “Fundamental Change under 5.50% Convertible Notes Indenture” with respect to Egalet Corporation’s (the “Company”) cash and cash equivalents, restricted cash and marketable securities as of June 30, 2018 is incorporated into this Item 2.02 by reference. 2.04 The information set forth in Item 3.01 below under the heading “Fundamental Change under 5.50% Convertible Notes Indenture” is incorporated into this Item 2.04 by reference. 3.01 On July 9, 2018, the Company received notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Nasdaq Hearings Panel has approved the transfer of the listing of the Company’s common stock from The Nasdaq Global Market to The Nasdaq Capital Market effective at the open of business on July 11, 2018 (the “Transfer”). | a18-17112_18k.htm |
| 2018-06-07 | 8-K | 2018-06-06 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (d) On June 6, 2018, the Board of Directors (the “Board”) of Egalet Corporation (the “Company”) appointed John Varian as a director of the Company. | a18-13533_58k.htm |
| 2018-05-25 | 8-K | 2018-05-24 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 As previously disclosed by Egalet Corporation (the “Company”) on a Current Report on Form 8-K filed with the Securities and Exchange Commission on November 24, 2017, the Company received a deficiency notice, dated November 24, 2017, from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with The Nasdaq Global Market continued listing requirement set forth in Nasdaq’s Listing Rule 5450(b)(2)(A) (the “Minimum Market Value Rule”), as the minimum market value of the Company’s common stock had been below $50 million for 30 consecutive business days. | a18-13533_48k.htm |
| 2018-05-24 | 8-K | 2018-05-24 | 8.01 Other Events | 8.01 On May 24, 2018, in connection with the expiration of the registration statement on Form S-3 (File No. 202807) of Egalet Corporation (the “Company”) originally declared effective on February 6, 2015 (the “Prior Registration Statement”), the Company filed a new prospectus supplement (the “Prospectus Supplement”) to the Company’s effective universal shelf registration statement on Form S-3 (File No. 333-209367), filed with the Securities and Exchange Commission on February 3, 2016 and relating to its existing “at the market offering” program (the “ATM Program”) pursuant to the Controlled Equity OfferingSM sales agreement (the “Sales Agreement”) previously entered into on July 2, 2015, by and between the Company and Cantor Fitzgerald & Co. (“Cantor”) as sales agent. | a18-13533_38k.htm |
| 2018-05-15 | 8-K | 2018-05-14 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On May 14, 2018, Egalet Corporation (the “Company”) held an annual meeting of stockholders (the “Annual Meeting”). | a18-13533_18k.htm |
| 2018-05-15 | 8-K | 2018-05-08 | 2.02 Results of Operations and Financial Condition | 2.02 On May 8, 2018, Egalet Corporation (the “Company”) issued a press release announcing its financial results for its first quarter ended March 31, 2018. | a18-13533_28k.htm |
| 2018-04-05 | 8-K | 2018-04-04 | 8.01 Other Events | 8.01 On April 4, 2018, Egalet US, Inc. and Egalet Ltd., subsidiaries of Egalet Corporation, (collectively, “Egalet” or the “Company”) filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Teva Pharmaceuticals USA, Inc. (“Teva”). | a18-9613_18k.htm |
| 2018-03-12 | 8-K | 2018-03-12 | 2.02 Results of Operations and Financial Condition | 2.02 On March 12, 2018, Egalet Corporation (the “Company”) issued a press release announcing its financial results for its fourth quarter and fiscal year ended December 31, 2017. | a18-7951_18k.htm |
| 2018-03-09 | 8-K | 2018-03-08 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 - Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. | a18-7951_28k.htm |
| 2018-02-23 | 8-K | 2018-02-23 | 8.01 Other Events | 8.01 On February 23, 2018, Egalet Corporation (the “Company”) and its subsidiary, Egalet, Ltd., received notice from Teva Pharmaceuticals USA, Inc. (“Teva”) that Teva has submitted an Abbreviated New Drug Application (“ANDA”) with the U.S. Food and Drug Administration (the “FDA”) seeking regulatory approval to market a generic version of ARYMO ER™ (morphine sulfate) extended-release tablets (“ARYMO ER”). | a18-7035_18k.htm |
| 2018-02-16 | 8-K | 2018-02-14 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders | 5.03 On February 14, 2018, Egalet Corporation (the “Company”) held a special meeting of stockholders (the “Special Meeting”). 5.07 At the February 14, 2018 Special Meeting, there were 37,493,308 shares of common stock present in person or by proxy, which represented 81.6% of the voting power of the shares of common stock entitled to vote at the Special Meeting, constituting a quorum for the transaction of business. | a18-6323_18k.htm |